Nasopharyngeal cancer malignancy biomarker and method thereof

a nasopharyngeal cancer and biomarker technology, applied in the field of nasopharyngeal cancer malignancy biomarker and hnrnp kbased biomarker, can solve the problem of negatively correlated hnrnp k expression with the overall survival rate, and achieve the effect of predicting the malignancy of nasopharyngeal cancer, preventing the spread of nasopharyngeal

US20100316996A1Inactive Publication Date: 2010-12-16CHANG GUNG UNIVERSITY
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Publication Date
2010-12-16
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative hnRNP K expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and realize early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] The present invention relates to a technology for testing cancer malignancy, particularly to an hnRNP K-based biomarker for testing the malignancy of nasopharyngeal cancer and a method thereof.DESCRIPTION OF THE RELATED ART

[0002] Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a member of the ribonucleoprotein family. HnRNP K can directly interact with DNA and RNA via the K homology domain and can regulate gene expression in different aspects, including transcription, translation and ligation. HnRNP K may induce canceration via regulating the expression of oncogenes c-myc and eIF4E. HnRNP K can respectively join with the internal ribosome entry site of c-myc and the polypyrimidine of the promoter of eIF4E to induce the expression of c-myc and eIF4E. As hnRNP K normally exists in the nucleus, it cannot undertake regulation and translation unless it transfers to cytoplasm. A recent paper pointed out that hnRNP K may cause the metastasis of fibrosarcom...

Examples

Embodiment Construction

[0012]The present invention addresses the malignancy test of nasopharyngeal cancer. As hnRNP K is highly expressed in nasopharyngeal cancer and clinically correlated with nasopharyngeal cancer, the present invention adopts hnRNP K as a biomarker of nasopharyngeal cancer. Below, a clinical embodiment is used to demonstrate the principle of the present invention and prove the efficacy of the present invention.

[0013]Related experiments proved that hnRNP K and the target thereof—thymidine phosphorylase (TP) are over-expressed in nasopharyngeal cancer. The abnormal hnRNP K expression and TP over-expression in cytoplasm correlates with the shorter overall survival period and the distant metastasis. A multivariate analysis shows that hnRNP K and TP in cytoplasm is the independent factors for prognosis.

[0014]Therefore, the present invention adopts hnRNP K as a biomarker of nasopharyngeal cancer to accurately and effectively test the malignancy of nasopharyngeal cancer. Refer to FIG. 1 a flo...